JPWO2022056459A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022056459A5 JPWO2022056459A5 JP2023516770A JP2023516770A JPWO2022056459A5 JP WO2022056459 A5 JPWO2022056459 A5 JP WO2022056459A5 JP 2023516770 A JP2023516770 A JP 2023516770A JP 2023516770 A JP2023516770 A JP 2023516770A JP WO2022056459 A5 JPWO2022056459 A5 JP WO2022056459A5
- Authority
- JP
- Japan
- Prior art keywords
- grna
- cells
- cell
- cell population
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078137P | 2020-09-14 | 2020-09-14 | |
| US63/078,137 | 2020-09-14 | ||
| PCT/US2021/050254 WO2022056459A1 (en) | 2020-09-14 | 2021-09-14 | Compositions and methods for cd5 modification |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023541458A JP2023541458A (ja) | 2023-10-02 |
| JPWO2022056459A5 true JPWO2022056459A5 (https=) | 2024-09-25 |
| JP2023541458A5 JP2023541458A5 (https=) | 2024-09-25 |
Family
ID=78086070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516770A Abandoned JP2023541458A (ja) | 2020-09-14 | 2021-09-14 | Ｃｄ５修飾のための化合物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240041932A1 (https=) |
| EP (1) | EP4211245A1 (https=) |
| JP (1) | JP2023541458A (https=) |
| WO (1) | WO2022056459A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250295695A1 (en) * | 2022-04-04 | 2025-09-25 | Vor Biopharma Inc. | Compositions and methods for mediating epitope engineering |
| EP4587570A2 (en) * | 2022-09-16 | 2025-07-23 | Arsenal Biosciences, Inc. | Immune cells with combination gene perturbations |
| KR20260051108A (ko) * | 2023-05-23 | 2026-04-15 | 비토리아 바이오테라퓨틱스, 인코포레이티드. | Cd5 유전자좌 영역에 삽입된 이종성 핵산 분자를 포함하는 유전자 변형 세포 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080254027A1 (en) | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
| WO2008121160A2 (en) | 2006-11-21 | 2008-10-09 | Xencor, Inc. | Optimized antibodies that target cd5 |
| MX2011000970A (es) | 2008-08-29 | 2011-03-15 | Symphogen As | Anticuerpos anti-cd5. |
| EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| EP3556858A3 (en) | 2014-04-09 | 2020-01-22 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating cystic fibrosis |
| US10900034B2 (en) | 2014-12-03 | 2021-01-26 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
| EP3280803B1 (en) | 2015-04-06 | 2021-05-26 | The Board of Trustees of the Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
| CN108290939B (zh) | 2015-10-16 | 2023-01-13 | 纽约市哥伦比亚大学理事会 | 用于抑制谱系特异性抗原的组合物和方法 |
| JP7109784B2 (ja) | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 遺伝子編集のための進化したＣａｓ９蛋白質 |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| AU2017388753A1 (en) | 2016-12-30 | 2019-07-11 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| SG11201907870VA (en) | 2017-02-28 | 2019-09-27 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| JP2020525537A (ja) * | 2017-06-12 | 2020-08-27 | エモリー ユニバーシティー | Ｔ細胞抗原標的キメラ抗原受容体（ｃａｒ）、及び細胞療法での使用 |
| US11718659B2 (en) | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
| CN111918877A (zh) | 2018-03-14 | 2020-11-10 | 美国卫生和人力服务部 | 抗cd33嵌合抗原受体及其用途 |
| SG11202011383VA (en) * | 2018-05-31 | 2020-12-30 | Univ Washington | Chimeric antigen receptor t cells (car-t) for the treatment of cancer |
| CN112823011A (zh) * | 2018-07-09 | 2021-05-18 | 加利福尼亚大学董事会 | 基于t细胞的免疫疗法的基因靶标 |
| CA3107383A1 (en) | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy |
| US20220133790A1 (en) * | 2019-01-16 | 2022-05-05 | Beam Therapeutics Inc. | Modified immune cells having enhanced anti-neoplasia activity and immunosuppression resistance |
| EP4034138A4 (en) * | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
-
2021
- 2021-09-14 WO PCT/US2021/050254 patent/WO2022056459A1/en not_active Ceased
- 2021-09-14 JP JP2023516770A patent/JP2023541458A/ja not_active Abandoned
- 2021-09-14 US US18/026,018 patent/US20240041932A1/en active Pending
- 2021-09-14 EP EP21789935.0A patent/EP4211245A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7625555B2 (ja) | 修飾されたガイドｒｎａ | |
| KR102532663B1 (ko) | 베타 이상헤모글로빈증의 치료를 위한 crispr/cas-관련 방법 및 조성물 | |
| US20230392131A1 (en) | Reprogrammable iscb nucleases and uses thereof | |
| JP2024073596A5 (https=) | ||
| JP2025512996A (ja) | アデノシンデアミナーゼ、塩基エディター及び応用 | |
| WO2017180711A1 (en) | Grna fusion molecules, gene editing systems, and methods of use thereof | |
| EP4244345A1 (en) | Targeted gene regulation of human immune cells with crispr-cas systems | |
| KR20010071227A (ko) | 무세포 키메라플라스티 및 이형이중나선 돌연변이성벡터를 진핵세포에 이용 | |
| US20240318165A1 (en) | Type i-b crispr-associated transposase systems | |
| JP2016501036A5 (https=) | ||
| US20220380758A1 (en) | Type i-b crispr-associated transposase systems | |
| Cao et al. | The multiplexed CRISPR targeting platforms | |
| CA3204429A1 (en) | Dna nuclease guided transposase compositions and methods of use thereof | |
| JPWO2022056489A5 (https=) | ||
| US20240218339A1 (en) | Class ii, type v crispr systems | |
| WO2023206871A1 (zh) | 一种优化的CRISPR/SpCas12f1系统、工程化向导RNA及其应用 | |
| US20230383272A1 (en) | Nucleic acid-guided nucleases and use thereof | |
| JPWO2022056459A5 (https=) | ||
| JPWO2020150478A5 (https=) | ||
| US20250223577A1 (en) | Hybrid crispr-cas systems and methods of use thereof | |
| WO2021183850A1 (en) | Compositions and methods for modifying a target nucleic acid | |
| JPWO2020237217A5 (https=) | ||
| CA3161896A1 (en) | Methods and compositions for high efficiency homologous repair-based gene editing | |
| US20250327054A1 (en) | Reprogrammable isrb nucleases and uses thereof | |
| US20230265421A1 (en) | Type ii crispr/cas9 genome editing system and the application thereof |